Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TARS)

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

GlobeNewswire March 31, 2026

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

GlobeNewswire March 23, 2026

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire February 26, 2026

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

GlobeNewswire February 23, 2026

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

GlobeNewswire February 18, 2026

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

GlobeNewswire February 17, 2026

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire November 24, 2025

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire November 5, 2025

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

GlobeNewswire November 4, 2025
View More News ››

Opinion & Analysis (NDAQ:TARS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS): Revolutionizing

http://beyondspx.com/2024/08/01/tarsus-pharmaceuticals-inc-nasdaq-tars-revolutionizing-eye-care-with-xdemvy-and-a-promising-pipeline/
MikeTester - August 2, 2024

$TARS ALL EYES ON TARSUS PHARMACEUTICALS!

$TARS ALL EYES ON TARSUS PHARMACEUTICALS!   Click Here
AviseAnalytics - July 2, 2021
View more Bullboard ››

Nuclear Vision Ltd.

Nuclear Vision Ltd.

Nuclear Vision Limited operates as a uranium exploration company. Its material property is the Regnault Project that consists ...
View More »

Podcasts